Webinar | Is Your Packaging PPWR Ready? Register Here

Visual Effect Innovations vs. NVIDIA Corporation – We think US8864304 and US9167235 could get Easily Invalidated

Authors

On December 1, 2016, Visual Effect LLC filed a lawsuit against NVIDIA Corporation for infringing two of its patents US8864304 and US9167235– for which it demanded a trial by jury.

Filed in the District Court for the Eastern District of Texas, according to the complaint, NVIDIA‘s active 3D glasses infringed primarily on Claim 1 of both the patents.

The US’304, a continuation application, which claims priority to 23 Jan 2001, claims the method of viewing a video for an electronically controlled spectacle, comprising a frame, left and a right lens having a light and dark state, and a control unit which controls the state of the lenses. According to the complaint, NVIDIA’s 3D glasses have all similar features, thereby infringing US’304.

The US’235, a continuation patent of US’304, claims a similar method, albeit with an enhanced scope [The claims of US’235 cover multiple states instead of the two states originally claimed in US’304]. Thus, according to the complaint, both patents are infringed by NVIDIA.

But when we came across this case, the first thought that came into our mind was- How could these patents be granted with a priority date as early as 2001? The concept itself was introduced in the 1970s, by the inventor of LCD shutter glasses Stephen McAllister. Further, many companies like Sega, Nintendo, and Panasonic have already worked on a similar concept in the 80s and 90s.

For quite some time, we have been conducting preliminary analysis on recent patent litigation cases to check if a plaintiff’s patent holds water or not? You can access the other analysis conducted here: our take on patent litigation

Taking the cue, we conducted a preliminary analysis and found that there were really good chances of invalidating the patent. According to our analysis, multiple loopholes in the examination procedure made it possible for the grant of these patents.

Also, much relevant prior art, including non-patent literature, was overlooked. According to our analysis, both US‘304 and US’235 could be easily invalidated.

We have converted the detailed preliminary analysis report into a downloadable PDF format. You can download the report from here:

Analysis by: Nikhil Gupta, Manager, Search Team, and Prasun Pal, Manager, Search Team.

Share This Article:

Authors

Related Articles

Table of Contents

More Insights For You

Emerging HVAC Startup Innovations

HVAC systems account for 20% of global building electricity consumption, making energy efficiency improvements critical to meeting decarbonization targets. Yet most innovation in this space has been limited to marginal

CERT Systems Scouted Interview

The chemical industry is responsible for over 5% of global greenhouse gas emissions, primarily because it relies on fossil fuels as raw materials. Nearly every product we use today (plastics,

strava vs garmin

“I’d be gutted if Garmin data stopped syncing with Strava,” said Sue Kay, a professional triathlete and a fitness coach. “Garmin gives me the data, but Strava gives me the

Emerging Dairy Industry Trends Top Trends and Predictions

Bet on the wrong trend, and 18 months later, you’re explaining why it didn’t work in the boardroom, instead of celebrating product success. Kerry learned this the hard way. In

Titanium Dioxide Alternatives in Pharmaceuticals

The European Commission has recently postponed the ban on TiO2 in medicinal products due to the lack of viable alternatives. This move highlights the overreliance on TiO2 and the need

video codec

As the world transitions into the metaverse, 8K streaming, and autonomous systems, the demand for a codec more powerful than H.266/VVC is no longer a distant vision. It’s an immediate

Cosmetic Industry Trends

Spot a trend too late, and you lose a decade chasing your competitors.  A 90-year-old beauty giant was slow to adapt to the rising trend of online shopping and social‑media

FDA DRUG APPROVALS 2025

In 2025, the FDA has approved 28 new therapies, each signaling how the next decade of pharma innovation and IP strategy will unfold. From oncology and rare diseases to quality-of-life

6G standardization

6G

As 6G standardization takes shape, the landscape is already showing signs of fragmentation. 6G Core: Telecom vs. Non-Telecom Who is Leading the Future Standards? 3GPP Contribution Split: The convergence of

Facing A Roadblock On Your Project?

Our Experts Are Here To Help.